Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: Anti-inflammatory glucocorticoid (GC) therapy often induces hyperglycemia due to insulin resistance and islet-cell dysfunction. Incretin-based therapies may preserve glucose tolerance and pancreatic islet-cell function. In this study, we hypothesized that concomitant administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes could protect against the GC-induced diabetogenic effects. Design and methods: Men with the metabolic syndrome but without diabetes received prednisolone 30 mg once daily plus sitagliptin 100 mg once daily (n=14), prednisolone (n=12) or sitagliptin alone (n=14) or placebo (n=12) for 14 days in a double-blind 2×2 randomized-controlled study. Glucose, insulin, C-peptide, and glucagon were measured in the fasted state and following a standardized mixed-meal test. β-cell function parameters were assessed both from a hyperglycemic–arginine clamp procedure and from the meal test. Insulin sensitivity (M-value) was measured by euglycemic clamp. Results: Prednisolone increased postprandial area under the curve (AUC)-glucose by 17% (P<0.001 vs placebo) and postprandial AUC-glucagon by 50% (P<0.001). Prednisolone reduced 1st and 2nd phase glucose-stimulated- and combined hyperglycemia–arginine-stimulated C-peptide secretion (all P≤0.001). When sitagliptin was added, both clamp-measured β-cell function (P=NS for 1st and 2nd phase vs placebo) and postprandial hyperglucagonemia (P=NS vs placebo) remained unaffected. However, administration of sitagliptin could not prevent prednisolone-induced increment in postprandial glucose concentrations (P<0.001 vs placebo). M-value was not altered by any treatment. Conclusion: Fourteen-day treatment with high-dose prednisolone impaired postprandial glucose metabolism in subjects with the metabolic syndrome. Concomitant treatment with sitagliptin improved various aspects of pancreatic islet-cell function, but did not prevent deterioration of glucose tolerance by GC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
Glucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Lambillotte, C., Gilon, P., & Henquin, J. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119175 · Cited by 419
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Risk of Diabetes Associated With Prescribed Glucocorticoids in a Large Population
Gulliford, M. C., Charlton, J., & Latinovic, R. (2006) · Diabetes Care · doi:10.2337/dc06-1499 · Cited by 211
Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men
van Raalte, D. H., Nofrate, V., Bunck, M. C., van Iersel, T., Elassaiss Schaap, J., Nässander, U. K., Heine, R. J., Mari, A., Dokter, W. H. A., & Diamant, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1034 · Cited by 170
Self-citationRosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2174-9 · Cited by 109
Self-citationYuen, K. C. J., McDaniel, P. A., & Riddle, M. C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04242.x · Cited by 58
Cited by
Tamez-Pérez, H. E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.1073 · Cited by 387
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
A practical guide for the management of steroid induced hyperglycaemia in the hospital
Aberer, F., Hochfellner, D. A., Sourij, H., & Mader, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102154 · Cited by 110
Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review
Bonaventura, A., & Montecucco, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.006 · Cited by 108
Metadata
- Authors
- van Genugten, R. E., van Raalte, D. H., Muskiet, M. H., Heymans, M. W., Pouwels, P. J. W., Ouwens, D. M., Mari, A., & Diamant, M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03
- Volume
- 170
- Issue
- 3
- Pages
- 429-439
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2130920067
- Cited by
- 46
- References
- 10
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. https://app.cochat.ai/papers/10.1530/eje-13-0610
- The paper
- van Genugten, R. E., van Raalte, D. H., Muskiet, M. H., Heymans, M. W., Pouwels, P. J. W., Ouwens, D. M., Mari, A., & Diamant, M. (2014). Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. European Journal of Endocrinology. https://doi.org/10.1530/eje-13-0610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.